Skip to main content

Viatris Inc Value Stock - Dividend - Research Selection

Viatris

ISIN: US92556V1061 , WKN: A2QAME

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Is Viatris (VTRS) Pricing Reflect Its Recent Multi‑Year Share Price Recovery

2026-01-24
If you are wondering whether Viatris might still offer value at its current share price, this article walks through what the numbers are really saying about the stock. The shares recently closed at US$13.21, with returns of 2.7% over 7 days, 7.9% over 30 days, 6.0% year to date, 23.9% over 1 year and 27.5% over 3 years, while the 5 year return sits at a 4.9% decline. Recent news coverage has focused on Viatris as a large U.S. listed pharmaceuticals and biotech company. This keeps investor...

Viatris (VTRS) Valuation Check After First International Inpefa Heart Failure Launch

2026-01-24
Viatris (VTRS) is back in focus after the company launched its heart failure treatment Inpefa in the United Arab Emirates, marking its first commercialization of the drug outside the U.S. and Europe. See our latest analysis for Viatris. The Inpefa launch lands at a time when momentum in Viatris' share price has been building, with a 30 day share price return of 7.92% and a 90 day share price return of 27.63%. The 1 year total shareholder return sits at 23.94%, compared with a weaker 5 year...

Viatris Earnings Preview: What to Expect

2026-01-22
Viatris is set to report its fourth-quarter earnings soon, with analysts forecasting a slight decline in profits.

3 Reasons to Sell VTRS and 1 Stock to Buy Instead

2026-01-22
What a time it’s been for Viatris. In the past six months alone, the company’s stock price has increased by a massive 41.5%, reaching $13.07 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

2026-01-20
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the launch of Inpefa® (sotagliflozin) in the United Arab Emirates (UAE), the first country within the Viatris territories to commercialize the treatment. Future launches are planned in multiple countries over the next several years, supporting Viatris' strategy to expand access to the treatment in key markets outside of the U.S. and Europe.

3 Cash-Producing Stocks with Questionable Fundamentals

2026-01-16
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

3 Volatile Stocks We Keep Off Our Radar

2026-01-15
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren’t prepared.

44th Annual J.P. Morgan Healthcare Conference

2026-01-13
2026-01-13. The following slide deck was published by Viatris Inc.

Viatris Inc. (VTRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2026-01-13
Viatris Inc. (VTRS) 44th Annual J.P.

Why Analysts See The Viatris (VTRS) Story Shifting With Affordable Medicines And A US$16 Target

2026-01-09
The recent update to Viatris centers on a refreshed US$16 price target, set against a fair value estimate that has inched from about US$12.44 to roughly US$12.67 as the affordable medicines theme gains attention. Analysts tying the higher target to this theme are effectively saying the model now gives slightly more credit to Viatris’ ability to fit ongoing demand for cost conscious healthcare options as 2026 approaches. Continue reading this article to see how you can keep on top of these...